Equities analysts expect Corvus Pharmaceuticals Inc (NASDAQ:CRVS) to announce ($0.40) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Corvus Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.41) and the highest estimate coming in at ($0.39). Corvus Pharmaceuticals posted earnings per share of ($0.58) in the same quarter last year, which would suggest a positive year over year growth rate of 31%. The business is scheduled to announce its next earnings results on Thursday, March 7th.
On average, analysts expect that Corvus Pharmaceuticals will report full-year earnings of ($1.78) per share for the current financial year, with EPS estimates ranging from ($1.81) to ($1.74). For the next year, analysts anticipate that the company will report earnings of ($1.59) per share, with EPS estimates ranging from ($1.65) to ($1.52). Zacks’ EPS calculations are a mean average based on a survey of research analysts that that provide coverage for Corvus Pharmaceuticals.
Corvus Pharmaceuticals (NASDAQ:CRVS) last released its quarterly earnings data on Thursday, November 1st. The company reported ($0.36) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.12.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. lifted its position in shares of Corvus Pharmaceuticals by 2.0% during the third quarter. Vanguard Group Inc. now owns 677,974 shares of the company’s stock worth $5,817,000 after purchasing an additional 13,578 shares in the last quarter. Renaissance Technologies LLC grew its position in shares of Corvus Pharmaceuticals by 22.2% during the third quarter. Renaissance Technologies LLC now owns 396,900 shares of the company’s stock worth $3,405,000 after acquiring an additional 72,000 shares during the last quarter. Citadel Advisors LLC acquired a new stake in Corvus Pharmaceuticals in the third quarter worth about $182,000. Bridgeway Capital Management Inc. lifted its holdings in Corvus Pharmaceuticals by 23.1% in the third quarter. Bridgeway Capital Management Inc. now owns 104,600 shares of the company’s stock worth $897,000 after purchasing an additional 19,600 shares during the period. Finally, Dimensional Fund Advisors LP lifted its holdings in Corvus Pharmaceuticals by 66.6% in the third quarter. Dimensional Fund Advisors LP now owns 260,701 shares of the company’s stock worth $2,237,000 after purchasing an additional 104,230 shares during the period. 87.42% of the stock is currently owned by institutional investors and hedge funds.
NASDAQ:CRVS traded up $0.29 on Wednesday, hitting $6.27. The stock had a trading volume of 1,414 shares, compared to its average volume of 78,899. The firm has a market capitalization of $175.11 million, a price-to-earnings ratio of -2.24 and a beta of -0.65. Corvus Pharmaceuticals has a 1-year low of $5.66 and a 1-year high of $13.91.
Corvus Pharmaceuticals Company Profile
Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies that are designed to harness the immune system to attack cancer cells. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in Phase I/Ib clinical trial for adenosine, an immune checkpoint.
Recommended Story: Marijuana Stocks Investing Considerations
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.